A systematic review of 19 studies found that repetitive transcranial magnetic stimulation (rTMS) improved sleep quality in people with insomnia disorder compared to sham treatment . The effect was stronger when rTMS was combined with medication, though the clinical significance of these improvements remains to be established.
Insomnia disorder affects millions of people worldwide and carries substantial health costs. Current first-line treatments like cognitive behavioral therapy for insomnia (CBT-I) have limited accessibility, while medications often come with side effects and dependency risks. This meta-analysis examined whether rTMS, a noninvasive brain stimulation technique that modulates cortical activity by delivering magnetic pulses through the scalp, could offer a viable alternative or adjunct treatment.
The analysis pooled data from 23 randomized controlled trials across 19 studies involving 1,690 adults with insomnia disorder. Researchers searched major medical databases including PubMed, Embase, Web of Science, and specialized Chinese databases (CNKI and Wanfang) through early 2024. The primary outcomes measured were sleep quality using standardized instruments: the Pittsburgh Sleep Quality Index (PSQI), the Insomnia Severity Index (ISI), and polysomnography-derived sleep efficiency (SE).
The results showed clear separation between rTMS and sham treatment groups. Participants receiving active rTMS demonstrated marked improvements in PSQI and ISI scores compared to sham recipients (p < 0.001 across both measures). Objective measures from polysomnography also favored rTMS, with the stimulation group showing better sleep efficiency (p = 0.003). When researchers examined rTMS combined with medication versus medication alone, the combination approach produced superior outcomes on PSQI scores (p = 0.003), suggesting additive benefits.
In subgroup analysis, after excluding one high-heterogeneity study, rTMS again outperformed other treatment comparisons on PSQI scores (p = 0.03). The researchers identified several factors that may influence treatment response: disease duration, treatment duration, and stimulation site (location on the brain where magnetic pulses were delivered). Low-frequency rTMS (LF-rTMS), a specific variant using slower pulse rates, appeared particularly safe and effective, though the review did not quantify exact response rates or effect sizes for these subgroups.
This meta-analysis strengthens the case that rTMS deserves consideration as an evidence-based option for insomnia, particularly for people who cannot access or tolerate conventional treatments. The consistent improvements across multiple sleep quality measures and the additive benefit when combined with medication suggest rTMS engages real neurobiological pathways involved in sleep regulation.
However, several important caveats apply. First, the studies reviewed varied considerably in methodology, rTMS protocols, and comparison conditions, which the authors addressed by excluding high-heterogeneity outliers. Second, while improvements were statistically significant, the abstract does not report effect sizes or the clinical meaningfulness of the changes (whether people felt substantially better). Third, long-term durability was not addressed: does benefit persist after treatment stops, or do effects fade? Fourth, the review identified disease duration, treatment duration, and stimulation site as influential factors but did not specify which combinations work best, limiting practical implementation guidance.
For someone considering rTMS for insomnia, realistic expectations matter. rTMS requires multiple sessions (typically 10-20 over weeks) in a clinical setting, making it more time-intensive than taking a supplement or practicing sleep hygiene basics. Cost and insurance coverage vary widely. Established first-line treatments like CBT-I, reading before bed, sleep temperature optimization, and morning sunlight exposure remain evidence-rich approaches worth pursuing first, especially if accessible. rTMS appears most compelling as an adjunct to medication when standard approaches have plateaued or as a primary option when other treatments are unavailable.
The evidence also suggests combining rTMS with medication outperforms either approach alone, though the study does not specify which medications or what dosing strategies were used. This underscores that rTMS should be coordinated with a qualified neurologist or psychiatrist who can tailor the stimulation protocol to your needs.
| Attribute | Details |
|---|---|
| Study Type | Systematic review and meta-analysis |
| Sample Size | 1,690 participants across 23 trials from 19 studies |
| Databases Searched | Cochrane Library, Embase, Web of Science, PubMed, CNKI, Wanfang |
| Primary Outcomes | Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI), polysomnography sleep efficiency |
| Key Finding | rTMS significantly improved sleep quality vs. sham (p < 0.001); rTMS + medication > medication alone (p = 0.003) |
| Evidence Tier | A tier (systematic review of RCTs) |
| Registration | PROSPERO: CRD42024626833 |
| Journal | Frontiers in Neuroscience |
| Publication Date | 2024 |
| PubMed ID | 42305778 |
Efficacy of repetitive transcranial magnetic stimulation for insomnia disorder: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Neuroscience. 2024. https://pubmed.ncbi.nlm.nih.gov/42305778
ProtocolEngine provides general health information based on published research. This is not medical advice. Consult a healthcare professional before starting any supplement or health protocol.